Premise: traditional disease-modifying antirheumatic drugs are less effective and safe than targeted therapy with biologic response modifiers in rheumatoid arthritis

por Fleischmann, R
Publicado 2003

Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of a Phase III, Multicenter Study

por Gladman, D, Fleischmann, R, Coteur, G, Woltering, F, Mease, P J
Publicado 2014

Comparative genomics and understanding of microbial biology.

por Fraser, C M, Eisen, J, Fleischmann, R D, Ketchum, K A, Peterson, S
Publicado 2000

Patients' experiences in a guided Internet- and App-based stress intervention for college students: A qualitative study

por Fleischmann, R.J., Harrer, M., Zarski, A.-C., Baumeister, H., Lehr, D., Ebert, D.D.
Publicado 2017

Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group

por Fleischmann, R, Mease, PJ, Schwartzman, S, Hwang, L-J, Soma, K, Connell, CA, Takiya, L, Bananis, E
Publicado 2016

Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis

por van der Heijde, D., Deodhar, A., Fleischmann, R., Mease, P. J., Rudwaleit, M., Nurminen, T., Davies, O.
Publicado 2017

Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blin...

por van der Heijde, D, Fleischmann, R, Wollenhaupt, J, Deodhar, A, Kielar, D, Woltering, F, Stach, C, Hoepken, B, Arledge, T, Mease, P J
Publicado 2014

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD st...

por Fleischmann, R, Vencovsky, J, van Vollenhoven, R F, Borenstein, D, Box, J, Coteur, G, Goel, N, Brezinschek, H-P, Innes, A, Strand, V
Publicado 2008

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

por Mease, P J, Fleischmann, R, Deodhar, A A, Wollenhaupt, J, Khraishi, M, Kielar, D, Woltering, F, Stach, C, Hoepken, B, Arledge, T, van der Heijde, D
Publicado 2014

Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients...

por Fautrel, B, Zhu, B, Taylor, P C, van de Laar, M, Emery, P, De Leonardis, F, Kannowski, C L, Nicolay, C, Kadziola, Z, De La Torre, I, Fleischmann, R
Publicado 2020

Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure

por Mease, P, Deodhar, A, Fleischmann, R, Wollenhaupt, J, Gladman, D, Leszczyński, P, Vitek, P, Turkiewicz, A, Khraishi, M, FitzGerald, O, Landewé, R, de Longueville, M, Hoepken, B, Peterson, L, van der Heijde, D
Publicado 2015